The cited FDA warning letter identifies products marketed with retatrutide and tirzepatide and records the agency's stated regulatory findings concerning the recipient. 1
A warning letter records FDA's position and requested response at the time it was issued. This update does not generalize those findings to unrelated products or report a later resolution. 1
What this source can tell us. PeptideScanner is reporting the cited regulator or label record. The summary does not extend that record into broader safety, effectiveness, or approval claims.